$250.90
0.03% today
Nasdaq, Nov 26, 02:48 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Target price 2024 - Analyst rating & recommendation

Alnylam Pharmaceuticals, Inc Classifications & Recommendation:

Buy
70%
Hold
24%
Sell
6%

Alnylam Pharmaceuticals, Inc Price Target

Target Price $305.77
Price $250.98
Potential
Number of Estimates 26
26 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc target price is $305.77. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 33 analysts: 23 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2025 of . Most analysts recommend the Alnylam Pharmaceuticals, Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 1.83 2.23
76.23% 22.06%
EBITDA Margin -12.48% 1.22%
82.52% 109.78%
Net Margin -24.81% -11.39%
78.52% 54.08%

27 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2024 . The average Alnylam Pharmaceuticals, Inc sales estimate is

$2.2b
Unlock
. This is
6.53% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.3b 11.68%
Unlock
, the lowest is
$2.0b 6.72%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.8b 76.23%
2024
$2.2b 22.06%
Unlock
2025
$2.6b 17.54%
Unlock
2026
$3.5b 34.77%
Unlock
2027
$4.5b 26.26%
Unlock
2028
$5.7b 28.72%
Unlock

7 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2024. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is

$27.3m
Unlock
. This is
120.63% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$266m 300.94%
Unlock
, the lowest is
$-110m 16.71%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-228m 69.20%
2024
$27.3m 111.95%
Unlock
2025
$41.1m 50.85%
Unlock
2026
$842m 1,947.98%
Unlock
2027
$2.7b 222.38%
Unlock
2028
$3.9b 42.76%
Unlock

EBITDA Margin

2023 -12.48% 82.52%
2024
1.22% 109.78%
Unlock
2025
1.57% 28.69%
Unlock
2026
23.83% 1,417.83%
Unlock
2027
60.84% 155.31%
Unlock
2028
67.47% 10.90%
Unlock

25 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2024. The average Alnylam Pharmaceuticals, Inc net profit estimate is

$-254m
Unlock
. This is
24.70% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-86.3m 74.43%
Unlock
, the lowest is
$-379m 12.21%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-454m 62.15%
2024
$-254m 43.95%
Unlock
2025
$-145m 43.08%
Unlock
2026
$387m 367.52%
Unlock
2027
$867m 123.87%
Unlock
2028
$1.6b 83.47%
Unlock

Net Margin

2023 -24.81% 78.52%
2024
-11.39% 54.08%
Unlock
2025
-5.52% 51.54%
Unlock
2026
10.95% 298.37%
Unlock
2027
19.41% 77.26%
Unlock
2028
27.67% 42.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.52 -1.97
62.15% 44.03%
P/E negative
EV/Sales 14.48

25 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.97
Unlock
. This is
24.81% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.67 74.43%
Unlock
, the lowest is
$-2.94 12.21%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.52 62.15%
2024
$-1.97 44.03%
Unlock
2025
$-1.12 43.15%
Unlock
2026
$3.00 367.86%
Unlock
2027
$6.73 124.33%
Unlock
2028
$12.34 83.36%
Unlock

P/E ratio

Current -95.75 143.82%
2024
-127.21 32.86%
Unlock
2025
-223.48 75.68%
Unlock
2026
83.54 137.38%
Unlock
2027
37.32 55.33%
Unlock
2028
20.34 45.50%
Unlock

Based on analysts' sales estimates for 2024, the Alnylam Pharmaceuticals, Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

14.48
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
14.51
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 15.43 28.48%
2024
14.48 6.15%
Unlock
2025
12.32 14.93%
Unlock
2026
9.14 25.80%
Unlock
2027
7.24 20.80%
Unlock
2028
5.62 22.31%
Unlock

P/S ratio

Current 15.45 30.28%
2024
14.51 6.13%
Unlock
2025
12.34 14.93%
Unlock
2026
9.16 25.80%
Unlock
2027
7.25 20.80%
Unlock
2028
5.63 22.31%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today